BioHale® Sucrose, part of the new and expanded BioHale® portfolio line, offers exceptional purity stabilization for biologics.
Goch, Germany (21 April 2021) – DFE Pharma, a global leader in pharmaceutical excipient solutions is excited to announce the launch of its new product line BioHale®, to address worldwide supply challenges for biopharmaceutical companies.
Recent developments in the field of biologics have provided unique therapy options for many of the world’s most challenging diseases, resulting in significant growth. To be in line with this market development, and to support pharmaceutical companies in securing supply and mitigating risk in these times of unpredictability, DFE Pharma has stepped into the excipient market for biologics.
With the launch of BioHale® Sucrose, DFE Pharma offers exceptional market purity and low endotoxin excipient to be used in formulation. This new addition to the company’s well-established excipients’ portfolio aids in stabilising biologics and offers drug developers and manufacturers worldwide the highest quality excipient technology and services to guarantee increase in advanced therapeutic formulation.
Valued as excipient partner for over a century to many of the top global pharmaceutical brands, across various dosage forms from oral solid, respiratory, ophthalmic or parenteral application, DFE Pharma is uniquely positioned to deliver best-in-class excipient solutions for biopharmaceutical applications. This move is consistent with the company’s strategy to offer proven expertise and reliability of supply where most needed.
Bas van Driel, CEO of DFE Pharma, commented: “As a trusted solution provider and development partner to leading pharma brands, we are committed now to supporting customers in the formulation process for efficacious delivery of biologics.”
Backed up by knowledge leadership and uninterrupted production capacity, DFE Pharma can help customers choose the right excipients for their biological formulation whilst benefitting from proven, best-in-class technical solutions and expertise. This is the next step in the company’s journey to expanding excipient excellence.
“Whether future challenges are economic, environmental, or epidemiological in nature, our ability to adapt is key. By expanding our excipient excellence to biopharma, we can secure success for a more far-ranging customer base and further contribute to helping people lead healthier lives,” van Driel added.
For more information on DFE Pharma’s BioPharma portfolio, visit Biopharma | DFE Pharma
About DFE Pharma
DFE Pharma is a global leader in pharmaceutical excipient solutions. We strive to develop, produce and supply the highest quality functional excipients for use in the pharmaceutical, biopharmaceutical and nutraceutical industries for respiratory, oral solid dose (OSD), ophthalmic and parenteral formulations.
Our excipients play an essential role as fillers, binders, disintegrants, and in stabilising active ingredients for release in a predictable and effective manner into the patient’s system. With over a century of experience and over 400+ people worldwide in over 100 countries serving over 5000 customers, DFE Pharma is committed to supporting (bio)pharmaceutical and nutraceutical companies in their journey to improve patients’ lives. We are driven by our vision to work with your future in mind.